Abstract
Efficacy Assessment of Cytomegalovirus-Specific Immunoglobulins for the Management of CMV Reactivation in High-Risk Hematopoietic Stem Cell Transplant Recipients
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
